First Securities: Initial rating for Ikon Medical (01789.HK) as "Buy", with steady growth in medium-term profits and accelerated expansion of overseas business.

According to the Wise Finance APP, Orient Securities released a research report stating that iKang Healthcare (01789.HK) has released its mid-term performance announcement for 2025. In the first half of 2025, the company achieved operating income of 694 million RMB (+5.60%) and a net profit attributable to shareholders of 161 million RMB (+15.3%). The company has been given a "buy" rating for the first time, with expected operating income for the years 2025 to 2027 to be 1.512 billion RMB, 1.751 billion RMB, and 2.027 billion RMB respectively; and net profits attributable to shareholders of listed companies to be 330 million RMB, 391 million RMB, and 463 million RMB respectively.